Summary
Regeneron Pharmaceuticals, Inc. has filed an 8-K report detailing a material definitive agreement. Specifically, on November 18, 2014, the company entered into the Second Amendment to its Master Terms and Conditions for Warrants with Credit Suisse Capital LLC. This amendment significantly alters the terms of outstanding warrants previously issued in connection with the company's 2011 convertible senior notes and related hedging activities. Key to investors, the Second Amendment reduces the number of warrants held by the Warrant Holder by 328,820, representing a 32.6% decrease, leaving 679,511 warrants outstanding. This reduction was achieved through a payment of $100.7 million by Regeneron to the Warrant Holder. This action likely reflects a strategic decision by Regeneron to manage its outstanding equity dilution and potentially to settle or modify financial instruments associated with its past debt offerings.
Key Highlights
- 1Regeneron entered into a Second Amendment to its Master Terms and Conditions for Warrants on November 18, 2014.
- 2The amendment was made with Credit Suisse Capital LLC (as assignee of Credit Suisse International), the Warrant Holder.
- 3The amendment reduces the number of outstanding warrants held by the Warrant Holder by 328,820.
- 4This represents a 32.6% reduction in the warrants held by the Warrant Holder.
- 5Following the amendment, 679,511 warrants remain outstanding with the Warrant Holder.
- 6Regeneron paid $100.7 million to the Warrant Holder in consideration for entering into this Second Amendment.
- 7The warrants were originally issued in 2011 in connection with Regeneron's 1.875% convertible senior notes and related hedging transactions.